Mr. Zajkowski Brings More Than 25 Years of Experience in Treasury, Corporate Finance, Tax, Risk Management, Accounting, and Financial Planning and Analysis
AUGUST 15, 2019—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has welcomed Thomas Zajkowski, CPA to its leadership team as Chief Financial Officer (CFO). In this role, Mr. Zajkowski will lead the development and execution of financial strategies to enable BioAgilytix’s continued success in serving customers across its global operations.
Mr. Zajkowski brings more than 25 years of experience managing finance functions in private equity-sponsored and publicly-traded companies, including multiple healthcare and life sciences organizations. Just prior to joining BioAgilytix, he served as Senior Vice President, Finance & Treasurer at Syneos Health, based in Raleigh, North Carolina. He has also held senior-level finance positions at M*Modal, a medical transcription company, and Edwards Lifesciences, a medical device manufacturer, as well as with Fortune 500 companies. He has successfully participated in and completed numerous capital raising and M&A transactions, and possesses diverse management and leadership experience in the areas of corporate finance, treasury, tax, risk management, accounting, and financial planning and analysis. He is a CPA and holds an MBA with a concentration in International Business from the University of Toledo.
“Tom’s wealth of experience in the global life sciences industry and proven financial leadership make him the ideal candidate for this pivotal position,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “He brings with him a unique understanding of our market, and will apply that perspective to financial strategies that will enable us to further solidify our infrastructure, investing in the right resources so we continue to meet the diverse bioanalytical needs of our customers and ultimately the patients they serve.”
“I look forward to supporting the important scientific work that BioAgilytix delivers to advance the drug development industry as whole,” said Mr. Zajkowski. “I consider it an honor to join such a seasoned and successful leadership team, as part of a company where every employee is fully aligned in the same mission. It is a privilege to ensure the financial future of a team that is dedicated to supporting the next generation of life-saving drugs.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.